|
1
|
Tai W, Qin B and Cheng K: Inhibition of
breast cancer cell growth and invasiveness by dual silencing of
HER-2 and VEGF. Mol Pharm. 7:543–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bartsch R, Wenzel C, Zielinski CC and
Steger GG: HER-2-positive breast cancer: hope beyond trastuzumab.
BioDrugs. 21:69–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Engel RH and Kaklamani VG: HER2-positive
breast cancer: current and future treatment strategies. Drugs.
67:1329–1341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dos Santos ML, Gimenes KP, Silva WA Jr and
Nagai MA: Transcriptome changes induced by docetaxel in human
mammary cell lines expressing different levels of ERBB2. Int J Mol
Med. 23:733–743. 2009.
|
|
5
|
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC
Jr and Liu J: Inhibition of breast and ovarian tumor growth through
multiple signaling pathways by using retrovirus-mediated small
interfering RNA against Her-2/neu gene expression. J Biol Chem.
279:4339–4345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Faltus T, Yuan J, Zimmer B, et al:
Silencing of the HER2/neu gene by siRNA inhibits proliferation and
induces apoptosis in HER2/neu-overexpressing breast cancer cells.
Neoplasia. 6:786–795. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choudhury A, Charo J, Parapuram SK, et al:
Small interfering RNA (siRNA) inhibits the expression of the
Her2/neu gene, upregulates HLA class I and induces apoptosis of
Her2/neu positive tumor cell lines. Int J Cancer. 108:71–77. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Menard S, Casalini P, Campiglio M, Pupa SM
and Tagliabue E: Role of HER2/neu in tumor progression and therapy.
Cell Mol Life Sci. 61:2965–2978. 2004.PubMed/NCBI
|
|
9
|
Coronado Martin PJ, Fasero Laiz M, Garcia
Santos J, Ramirez Mena M and Vidart Aragon JA: Overexpression and
prognostic value of p53 and HER2/neu proteins in benign ovarian
tissue and in ovarian cancer. Med Clin. 128:1–6. 2007.(In
Spanish).
|
|
10
|
Still IH, Vince P and Cowell JK: The third
member of the transforming acidic coiled coil-containing gene
family, TACC3, maps in 4p16, close to translocation breakpoints in
multiple myeloma, and is upregulated in various cancer cell lines.
Genomics. 58:165–170. 1999. View Article : Google Scholar
|
|
11
|
Still IH, Hamilton M, Vince P, Wolfman A
and Cowell JK: Cloning of TACC1, an embryonically expressed,
potentially transforming coiled coil containing gene, from the 8p11
breast cancer amplicon. Oncogene. 18:4032–4038. 1999. View Article : Google Scholar
|
|
12
|
Ray ME, Yang ZQ, Albertson D, et al:
Genomic and expression analysis of the 8p11-12 amplicon in human
breast cancer cell lines. Cancer Res. 64:40–47. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gergely F, Karlsson C, Still I, Cowell J,
Kilmartin J and Raff JW: The TACC domain identifies a family of
centrosomal proteins that can interact with microtubules. Proc Natl
Acad Sci USA. 97:14352–14357. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Conte N, Charafe-Jauffret E, Delaval B, et
al: Carcinogenesis and translational controls: TACC1 is
down-regulated in human cancers and associates with mRNA
regulators. Oncogene. 21:5619–5630. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rhodes DR, Barrette TR, Rubin MA, Ghosh D
and Chinnaiyan AM: Meta-analysis of microarrays: interstudy
validation of gene expression profiles reveals pathway
dysregulation in prostate cancer. Cancer Res. 62:4427–4433.
2002.PubMed/NCBI
|
|
16
|
Line A, Slucka Z, Stengrevics A, Li G and
Rees RC: Altered splicing pattern of TACC1 mRNA in gastric cancer.
Cancer Genet Cytogenet. 139:78–83. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Conte N, Delaval B, Ginestier C, et al:
TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene.
22:8102–8116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nguyen HG, Chinnappan D, Urano T and Ravid
K: Mechanism of Aurora-B degradation and its dependency on intact
KEN and A-boxes: identification of an aneuploidy-promoting
property. Mol Cell Biol. 25:4977–4992. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghayad SE, Vendrell JA, Bieche I, et al:
Identification of TACC1, NOV, and PTTG1 as new candidate genes
associated with endocrine therapy resistance in breast cancer. J
Mol Endocrinol. 42:87–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ryser S, Dizin E, Jefford CE, et al:
Distinct roles of BARD1 isoforms in mitosis: full-length BARD1
mediates Aurora B degradation, cancer-associated BARD1beta
scaffolds Aurora B and BRCA2. Cancer Res. 69:1125–1134. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Devilard E, Bladou F, Ramuz O, et al:
FGFR1 and WT1 are markers of human prostate cancer progression. BMC
Cancer. 6:2722006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilson KS, Roberts H, Leek R, Harris AL
and Geradts J: Differential gene expression patterns in
HER2/neu-positive and -negative breast cancer cell lines and
tissues. Am J Pathol. 161:1171–1185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ueno NT, Yu D and Hung MC:
Chemosensitization of HER-2/neu-overexpressing human breast cancer
cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene.
15:953–960. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng LS, Zha Z, Xi JJ, Jiang B, Liu J and
Yao XB: Downregulation of HER2 by adenovirus-mediated RNA
interference and its inhibitory effect on growth of SKBR3 breast
cancer cell. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 23:691–695.
2007.(In Chinese).
|
|
25
|
Verri E, Guglielmini P, Puntoni M, et al:
HER2/neu oncoprotein overexpression in epithelial ovarian cancer:
evaluation of its prevalence and prognostic significance. Clinical
study. Oncology. 68:154–161. 2005. View Article : Google Scholar
|
|
26
|
Nalwoga H, Odida M and Wabinga H: c-erbB-2
oncoprotein over-expression in breast cancer and its relationship
to histology and grade in a Ugandan population. East Afr Med J.
83:411–415. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cornolti G, Ungari M, Morassi ML, et al:
Amplification and overexpression of HER2/neu gene and HER2/neu
protein in salivary duct carcinoma of the parotid gland. Arch
Otolaryngol Head Neck Surg. 133:1031–1036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoon S, Lee MY, Park SW, et al:
Up-regulation of acetyl-CoA carboxylase alpha and fatty acid
synthase by human epidermal growth factor receptor 2 at the
translational level in breast cancer cells. J Biol Chem.
282:26122–26131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cully M, Shiu J, Piekorz RP, Muller WJ,
Done SJ and Mak TW: Transforming acidic coiled coil 1 promotes
transformation and mammary tumorigenesis. Cancer Res.
65:10363–10370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee MJ, Gergely F, Jeffers K, Peak-Chew SY
and Raff JW: Msps/XMAP215 interacts with the centrosomal protein
D-TACC to regulate microtubule behaviour. Nat Cell Biol. 3:643–649.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marmor MD, Skaria KB and Yarden Y: Signal
transduction and oncogenesis by ErbB/HER receptors. Int J Radiat
Oncol Biol Phys. 58:903–913. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gabillard JC, Ulisse S, Baldini E, et al:
Aurora-C interacts with and phosphorylates the transforming acidic
coiled-coil 1 protein. Biochem Biophys Res Commun. 408:647–653.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Knuefermann C, Lu Y, Liu B, et al:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
